Urinary thromboxanes in dogs with conditions predisposing to thrombosis

Conway, Elizabeth (2020) Urinary thromboxanes in dogs with conditions predisposing to thrombosis. MVM(R) thesis, University of Glasgow.

Abstract

A number of canine diseases are associated with an increased risk of thrombo-embolic disease at the population level. These include common conditions such as immune-mediated haemolytic anaemia (IMHA), protein-losing nephropathies (PLN), and protein-losing enteropathies (PLE). At present there is no reliable way of predicting which individual patients are at risk of thrombosis, nor do we know whether the risk to an individual remains constant over time or fluctuates throughout the course of their disease. One of the mechanisms implicated in prothrombotic states is increased platelet activation. There are several ways of measuring platelet activation, which can be grouped into two main categories: platelet function assays and markers of platelet activation. These platelet activation markers can either be molecules expressed on the platelet surface or substances secreted when platelets are activated. Thromboxane A2 is one such substance. Serum levels of Thromboxane A2 can be indirectly assessed via measurement of its metabolites in urine, including urinary 11-dehydrothromboxane B2 (u-11dTXB). In humans, urine thromboxanes are used as biomarkers of thrombotic risk in several situations.

The aims of this study were threefold. Firstly, to assess whether urine thromboxanes are increased in dogs with IMHA, PLN and PLE. Secondly, to assess whether urine thromboxanes correlate with markers of disease severity, survival, or incidence of thrombosis in dogs with IMHA. And finally, to describe the change in urine thromboxane levels over the course of treatment of dogs with IMHA.

In this thesis I have shown that the u11-dTXB:Cr is increased in dogs with IMHA and PLE compared to healthy controls. I found no evidence of an association between u11-dTXB:Cr and markers of disease severity, survival or incidence of thrombosis in the subset of dogs with IMHA. The increase in u11-dTXB:Cr compared to healthy dogs was sustained over the first 6 weeks of treatment in the surviving dogs with IMHA. These findings have added to our knowledge of urinary thromboxanes as potential biomarkers of platelet activation in dogs with prothrombotic conditions.

• Item Type: Thesis (MVM(R))
• Qualification Level: Masters
• Keywords: urinary thromboxanes, platelet activation, thrombosis, canine, immune-mediated haemolytic anaemic, protein-losing nephropathy, protein-losing enteropathy.
• Subjects: S Agriculture > SF Animal culture > SF600 Veterinary Medicine
• Colleges/Schools: College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine > Small Animal Clinical Sciences
• Supervisor's Name: Ridyard, Ms. Alison
• Date of Award: 2020
• Depositing User: Miss Elizabeth Conway
• Unique ID: glathesis:2020-81534
• Copyright: Copyright of this thesis is held by the author.
• Date Deposited: 15 Apr 2021 13:58
• Last Modified: 15 Apr 2021 14:04
• Thesis DOI: 10.5525/gla.thesis.81534
• URI: https://theses.gla.ac.uk/id/eprint/81534